Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial is a research paper published in Journal of Investigative Dermatology (2022). On theSindex it has a DataRank of 0.601. It has been cited 54 times.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.601
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: R21AR066286
National Institutes of Health
Grant: 1R21AR066286-01
Treatment of Dermatomyositis with Ajulemic Acid, a Non-Psychoactive Cannabinoid
NIAMS NIH HHS
Grant: R01 AR076766
FWCI
7.71
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals